CellServe GmbH
CellServe GmbH is a Berlin-based biotechnology company specializing in the development and marketing of heart tissue-specific cells for regenerative therapy. It focuses on using novel, specialized cells derived from patient’s own heart biopsies to treat severe heart muscle weakness, aiming to improve quality of life and prolong life through innovative, minimally invasive, and affordable therapies. The company's technology involves cultivating cardiac-derived adherent proliferating cells (CardAP cells) from patient tissue for personalized treatment, with ongoing development of allogeneic 'off-the-shelf' products to enhance scalability and accessibility.
Industries
Nr. of Employees
small (1-50)
CellServe GmbH
Charitéplatz 1, internal: Virchowweg 11, 10117 Berlin, Germany
Products
Heart tissue-derived proliferative cardiac cell therapy (autologous; allogeneic development in progress)
Therapeutic cell product derived from patient heart biopsies, expanded ex vivo under GMP conditions and administered back to the patient (intravenous or intramyocardial) to improve cardiac function and reduce fibrosis; development pathway includes an allogeneic off-the-shelf variant for large-scale use.
Heart tissue-derived proliferative cardiac cell therapy (autologous; allogeneic development in progress)
Therapeutic cell product derived from patient heart biopsies, expanded ex vivo under GMP conditions and administered back to the patient (intravenous or intramyocardial) to improve cardiac function and reduce fibrosis; development pathway includes an allogeneic off-the-shelf variant for large-scale use.
Services
Strategy and planning support for development, manufacturing scale-up and market introduction of heart tissue-derived cell therapies, including investor engagement.
Strategy and planning support for development, manufacturing scale-up and market introduction of heart tissue-derived cell therapies, including investor engagement.
Expertise Areas
- Regenerative medicine
- Cardiac cell therapy development
- Autologous and allogeneic cell therapy strategies
- GMP cell therapy manufacturing
Key Technologies
- Isolation of cardiac cells from biopsy tissue
- GMP clean-room cell expansion
- Cell proliferation-based expansion processes
- Allogeneic batch manufacturing and cell banking
News & Updates
Scientific publication discussing the potential of endomyocardial biopsy-derived adherent proliferating cells for cardiac tissue engineering.
Study on the effects of human cardiac-derived adherent proliferating cells in reducing myocarditis in mice.
Research on the immune properties of CAP cells in cardiac therapy.
Study on how human cardiac biopsy-derived cells can reduce cardiac remodeling induced by Angiotensin II.
Research on the pro-angiogenic effects of biopsy-derived cells for cardiac regeneration.
Study on stromal cells derived from biopsy specimens and their effect on cardiac remodeling.
Scientific publication discussing the potential of endomyocardial biopsy-derived adherent proliferating cells for cardiac tissue engineering.
Study on the effects of human cardiac-derived adherent proliferating cells in reducing myocarditis in mice.
Research on the immune properties of CAP cells in cardiac therapy.
Study on how human cardiac biopsy-derived cells can reduce cardiac remodeling induced by Angiotensin II.
Research on the pro-angiogenic effects of biopsy-derived cells for cardiac regeneration.
Study on stromal cells derived from biopsy specimens and their effect on cardiac remodeling.